BioTime Co-CEO Dr. Michael West to Deliver Keynote Presentation at GTC Bio Stem Cell Summit on April 6
April 04 2017 - 7:00AM
Business Wire
Will Present on the Promise of Pluripotent
Cells in Advanced Therapeutics and the Company’s Plans to Develop
Applications in Human Aging
BioTime, Inc. (NYSE MKT:BTX), a clinical-stage
biotechnology company developing and commercializing products
addressing degenerative diseases, today announced that Co-Chief
Executive Officer Michael D. West, Ph.D., is delivering a keynote
presentation at the GTC Bio Stem Cell Summit, on April 6 at the
Hyatt Regency in Boston, Massachusetts.
Titled “The Promise of Pluripotency in the Manufacture of
Advanced Cell-Based Therapeutics,” Dr. West’s keynote presentation
is scheduled for Thursday, April 6 at 10:40 a.m. EDT. It will
provide an industry update on therapeutic uses of human pluripotent
cell-based regenerative medicine, including BioTime’s
clinical-stage OpRegen® and Renevia® programs. Dr. West will also
discuss the company’s preclinical products in development for Type
II diabetes and heart disease, as well as the emerging field of
induced tissue regeneration (iTRTM) and their potential impact on
the future of human aging.
More information about the Stem Cell Summit is available at
www.gtcbio.com/conferences/stem-cell-summit/.
More information on iTR is available via this video:
https://www.youtube.com/watch?v=Owx2-jzgJHQ.
About BioTime
BioTime is a clinical-stage biotechnology company focused on
developing and commercializing products addressing degenerative
diseases. Our clinical programs are based on two platform
technologies: pluripotent stem cells and cell/drug delivery
platform technologies. The foundation of our core therapeutic
technology platform is pluripotent cells that are capable of
becoming any of the cell types in the human body. The foundation of
our cell delivery platform is its HyStem® cell and drug delivery
matrix technology. The Company’s current clinical programs are
targeting three primary sectors, aesthetics, ophthalmology and
cell/drug delivery. We also have significant equity holdings in two
publicly traded companies, Asterias Biotherapeutics, Inc.
(“Asterias”) and OncoCyte Corporation (“OncoCyte”), which we
founded and which, until recently, were our majority-owned
consolidated subsidiaries.
BioTime common stock is traded on the NYSE MKT and TASE under
the symbol BTX. For more information, please visit
www.biotimeinc.com or connect with the company on Twitter,
LinkedIn, Facebook, YouTube, and Google+.
To receive ongoing BioTime corporate communications, please
click on the following link to join our email alert list:
http://news.biotimeinc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170404005517/en/
Investor Contact:EVC Group, Inc.Brian Moore,
310-770-0389bmoore@evcgroup.comorMedia
Contact:Gotham Communications, LLCBill Douglass,
646-504-0890bill@gothamcomm.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Sep 2023 to Sep 2024